Curative Biotechnology, Inc. Announces Letter to Shareholders
Curative Biotechnology (OTC: CUBT) announced a strategic redirection focused on sublicensing and manufacturing partnerships, a revised reverse stock split, and withdrawal of a planned S-1 public offering.
Key actions: pursuing a sublicence/manufacturing agreement for its metformin-based eye drops; targeting simultaneous human Dry AMD and canine indications (CPRA with a single 24-dog accelerated trial; PRA with ~300-dog effectiveness trial); withdrawing the S-1; and approving a 150-to-1 reverse split (replacing 400-to-1) pending FINRA approval. The company also plans to apply to uplist to the OTCQB after the sublicense and reverse split.
Curative Biotechnology (OTC: CUBT) ha annunciato una ricaduta strategica incentrata su sublicenze e partnership di produzione, una revisione dello stock split inverso e il ritiro di una prevista offerta pubblica S-1.
Azioni chiave: perseguire un accordo di sublicenza/produzione per i suoi colliri a base di metformina; mirare a indicazioni simultanee sia nell'uomo con Dry AMD che nei cani (CPRA con un singolo trial accelerato di 24 cani; PRA con ~300 cani di efficacia); ritirare l'S-1; e approvare un reverse split 150 a 1 (in sostituzione di 400 a 1) in attesa dell'approvazione FINRA. L'azienda prevede inoltre di richiedere l'up listing sul OTCQB dopo la sublicenza e lo split inverso.
Curative Biotechnology (OTC: CUBT) anunció una reorientación estratégica centrada en la sublicencia y asociaciones de fabricación, una revisión del reverse stock split y la retirada de una oferta pública S-1 planeada.
Acciones clave: buscar un acuerdo de sublicencia/producción para sus gotas oftálmicas basadas en metformina; apuntar a indicaciones simultáneas de Dry AMD humano y caninas (CPRA con un ensayo acelerado de 24 perros; PRA con ~300 perros de eficacia); retirar el S-1; y aprobar un reverse split de 150 a 1 (reemplazando 400 a 1) pendiente de la aprobación de FINRA. La compañía también planea solicitar cotizar en el OTCQB tras la sublicencia y el reverse split.
Curative Biotechnology (OTC: CUBT)은 재LICensing 및 제조 파트너십에 초점을 맞춘 전략적 방향 전환, 개정된 역주식분할, 및 계획된 S-1 공개모집의 철수를 발표했습니다.
주요 조치: 메트포르민 기반 눈 점적액에 대한 서브라이선스/제조 계약 추구; 인간의 건성 황반변성(Dry AMD)과 개의 적응증을 동시에 겨냥(CPRA는 24마리 개의 가속 테스트 단일; PRA는 약 300마리의 개 효과 시험); S-1 철회; 그리고 역분할 150대 1 (기존 400대 1을 대체) FINRA 승인을 대기. 또한 서브라이선스 및 역분할 후 OTCQB로 상장 상향을 신청할 계획입니다.
Curative Biotechnology (OTC: CUBT) a annoncé une réorientation stratégique axée sur les sublicences et les partenariats de fabrication, une révision du reverse stock split et le retrait d'une offre publique S-1 prévue.
Actions clés : poursuivre un accord de sublicence/production pour ses gouttes ophtalmiques à base de metformin; viser des indications humaines de DME sèche (Dry AMD) et canines simultanément (CPRA avec un essai accéléré de 24 chiens; PRA avec environ 300 chiens d'efficacité) ; retrait du S-1 ; et approuver un split inverse de 150 à 1 (au lieu de 400 à 1) en attente de l'approbation FINRA. L'entreprise prévoit également de demander une uplisting vers le OTCQB après la sublicence et le split inverse.
Curative Biotechnology (OTC: CUBT) kündigte eine strategische Neuausrichtung an, die sich auf Sub-Lizenzierung und Fertigungspartnerschaften, eine überarbeitete Rückwärtsaktienaufteilung und den Rückzug eines geplanten S-1- Börsengangs konzentriert.
Schritte im Überblick: Verfolgung einer Sub-Lizenz-/Fertigungsvereinbarung für seine metforminbasierten Augentropfen; gleichzeitige Zielsetzung auf humane Dry AMD- und Canine-Indikationen (CPRA mit einem einzigen beschleunigten 24-Hunde-Studie; PRA mit ca. 300 Hunden Wirksamkeitsstudie); Rückzug des S-1; und Genehmigung einer Rückwärtssplit 150 zu 1 (statt 400 zu 1) in Erwartung der FINRA-Genehmigung. Das Unternehmen plant außerdem, nach der Sub-Lizenz und dem Rückwärtssplit auf den OTCQB zu listen.
Curative Biotechnology (OTC: CUBT) أعلنت توجيهاً استراتيجياً جديداً يركّز على التراخيص الفرعية وشراكات التصنيع، وتعديلاً في التقسيم العكسي للأسهم، وسحب طرح عام أولي من نوع S-1 المخطط.
الإجراءات الرئيسية: التطلع إلى اتفاق ترخيص فرعي/تصنيع لمنتجاته قطرات العين المعتمدة على الميتفورمين; استهداف مؤشرات مشتركة للبشر من AMD الجاف وعيوب الكلاب في آن واحد (CPRA مع تجربة تسريع لـ 24 كلباً؛ PRA مع تجربة كفاءة لـ ~300 كلب)؛ سحب S-1؛ والموافقة على تجزئة عكسية 150 إلى 1 (تحل محل 400 إلى 1) بانتظار موافقة FINRA. كما تخطط الشركة للتقدم لإدراج في OTCQB بعد الترخيص الفرعي والتقسيم العكسي.
- Pursuing sublicence could provide non-dilutive upfront and milestone funding
- Targeting CPRA with a single 24-dog accelerated trial for faster approval
- Revised reverse split reduced to 150-to-1 from 400-to-1
- Withdrawal of S-1 halts planned public offering and related capital access
- Sublicense negotiations are not guaranteed to result in any definitive agreement
- Reverse split and uplist remain subject to FINRA and OTCQB approval timing
Strategic Update and New Path to Value Creation
Palm Beach Gardens, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced the following update to shareholders.
Dear fellow shareholders and interested investors,
We are writing to provide an important update on our business strategy and operational path forward. The Company has been actively pursuing the most efficient and value-accretive route to advance our primary clinical program, the metformin-based eye drops licensed from the National Eye Institute. We are pleased to announce significant changes that we believe will substantially accelerate and de-risk our development path and place us on a sounder financial footing.
These changes include the establishment of a strategic partnership with a key industry player, a revised capital structure, and the official termination of our previous public offering plan.
Key Strategic Developments
1. Strategic Sublicense and Manufacturing Partnership
The Company has decided to seek a manufacturing and/or full product development sublicense agreement for its metformin-based eye drops. We believe this type of relationship will:
- Significantly de-risk the operational execution of our trial(s) and ensure a clear, reliable supply chain;
- Provide additional non-dilutive funding via upfront and clinical milestone payments;
- Accelerate the pathway for future commercialization for intermediate Dry AMD and other degenerative eye diseases.
The Company is in active negotiations with potential partners and believes this process could be completed prior to year end. Of course, there can be no assurance that any of these negotiations will result in a definitive agreement or that any transaction will close.
In addition to pursuing degenerative eye diseases in humans, the Company will focus on similar diseases in canines (K9). Two indications in particular are:
- Progressive Retinal Atrophy (PRA), with an estimated prevalence in the U.S. of just under six million dogs;
- Central Progressive Retinal Atrophy (CPRA), with an estimated prevalence in the U.S. of under 80,000 diagnoses per year.
CPRA is a K9 disease that closely mimics human Dry AMD and is eligible for the Minor Uses in Major Species accelerated approval pathway, usually requiring a smaller, single 24-dog trial relying heavily on preclinical work to establish reasonable expectation of effectiveness for conditional marketing approval from the FDA Center for Veterinary Medicine (CVM).
We intend to pursue CPRA as the first K9 indication, simultaneously with human Dry AMD, and believe the preclinical data already created for our human trial will provide the evidence of effectiveness required by the CVM. PRA will follow with a single effectiveness trial of roughly 300 dogs.
The veterinary ophthalmic drug market is estimated between
2. Withdrawal of S-1 Registration Statement and Change to Reverse Stock Split Ratio
To better align our capital structure with the Company’s updated strategic direction, the Board has taken two key actions:
- Withdrawal of S-1: The Company will formally file to withdraw the previously planned S-1 public offering.
- Revised Reverse Stock Split: The Board has approved a revised 150-to-1 reverse split, replacing the prior 400-to-1 requirement.
The reverse split remains subject to FINRA approval, which historically may take weeks to months. There is no assurance of approval or of any impact on the Company’s capital needs.
Path to OTCQB Uplisting
Following execution of the strategic sublicense/manufacturing agreement and completion of the smaller reverse split, the Company intends to submit an application to uplist to the OTCQB Venture Market.
- Increased visibility and accessibility to investors, including institutions;
- Enhanced transparency and potential improvement in share liquidity;
- Positioning for a future uplisting to a national exchange when appropriate.
There is no assurance that the application to uplist will be accepted or that the Company will achieve these objectives.
Conclusion
Our new direction reflects management’s and the Board’s commitment to establishing a more sustainable, de-risked, and strategically aligned future. We believe these actions position Curative Biotech for meaningful advancement of our clinical program and long-term value creation.
Sincerely,
The Management of Curative Biotechnology
Future Curative Biotechnology Press Releases and Updates
Interested shareholders and investors may request notifications by emailing ir@curativebiotech.com
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc. is a development-stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with an emphasis on rare disease indications. Curative Biotech currently has programs in degenerative eye disease, infectious disease, and neuro-oncology.
The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its first therapeutic candidate is a metformin-based reformulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is targeted for 2026 under a Cooperative Research and Development Agreement (CRADA) with the NEI.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. These risks include, but are not limited to, the Company's ability to obtain regulatory approvals, secure sufficient funding, generate market acceptance, and manage operational challenges.
Readers are encouraged to review the Company’s disclosures filed with OTC Markets for a detailed discussion of risk factors. The Company undertakes no obligation to update any forward-looking statements except as required by law.
Contact:
Paul Michaels, Executive Chairman
Office: 917-492-8855 Direct
or
Investor Relations
Curative Biotech (CUBT)
ir@curativebiotech.com
FAQ
What did Curative Biotechnology (CUBT) announce on November 18, 2025?
How will the 150-to-1 reverse split affect CUBT shareholders?
What is Curative Biotechnology’s plan for canine indications and trial sizes (CUBT)?
Will Curative Biotechnology (CUBT) still pursue a public offering?
When does Curative Biotechnology plan to uplist to the OTCQB (CUBT)?
Does Curative Biotechnology guarantee a sublicense or regulatory acceptance for its trials (CUBT)?
